SIETES :: 92833 citas

Resultados de la búsqueda por DERMATOLÓGICOS REFINAR BÚSQUEDA

1.

Anónimo. Insect repellents. Med Lett Drugs Ther 2019;61:26 de agosto. [Ref.ID 103164]

2.

Anónimo. Ginkgo biloba: to be avoided due to severe adverse effects. Prescrire Int 2019;28:155-6. [Ref.ID 103129]

3.

Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

4.

Frey N, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. Stevens–Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: a population-based case–control study. Drug Saf 2019;42:enero. [Ref.ID 103028]

5.

Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]

6.

Costa CS, Bagatin E, Martimbianco ALC, da Silva EMK, Lúcio MM, Magin P, Riera R. Oral isotretinoin for acne. Cochrane Database of Systematic Reviews 2018:24 de noviembre. [Ref.ID 102889]

7.

Xu C, Chen Y-P, Du X-J, Liu J-Q, Huang C-L, Chen L, Zhou G-Q, Li W-F, Mao Y-P, Hsu C, Liu Q, Lin A-H, Tang L-L, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018;363:8 de noviembre. [Ref.ID 102847]

8.

Pottegård A, Pedersen SA, Alba S, Schmidt J, Hölmich LR, Friis S, Gaist D. Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern Med 2018;178:1120-2. [Ref.ID 102645]

9.

Maya Y, Ota M. Drug-induced localised scleroderma. BMJ 2018;360:12 de abril. [Ref.ID 102643]

10.

Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol 2018;154:1 de abril. [Ref.ID 102558]

11.

Imatoh T, Sai K, Fukasawa C, Hinomura Y, Nakamura R, Okamoto-Uchida Y, Segawa K, Saito Y. Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. Eur J Clin Pharmacol 2017;73:1643-53. [Ref.ID 102180]

12.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

13.

Anónimo. Fingolimod (Gilenya): nuevas contraindicaciones de uso en pacientes con patología cardiaca subyacente y recomendaciones de revisiones dermatológicas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:6 de noviembre. [Ref.ID 102124]

14.

Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]

15.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorenzton M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017:11 de septiembre. [Ref.ID 102052]

16.

Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol 2017;83:927-30. [Ref.ID 101972]

17.

Walter SR, Day RO, Gallego B, Westbrook JI. The impact of serious adverse drug reactions: a population-based study of a decade of hospital admissions in New South Wales, Australia. Br J Clin Pharmacol 2017;83:416-26. [Ref.ID 101933]

18.

Ramírez E, Medrano-Casique N, Tong HY, Bellón T, Cabañas R, Fiandor A, González-Ramos J, Herranz P, Trigo E, Muñoz M, Borobia AM, Carcas AJ, Frías J. Eosinophilic drug reactions detected by a prospective pharmacovigilance programme in a tertiary hospital. Br J Clin Pharmacol 2017;83:400-15. [Ref.ID 101932]

19.

Finch A, Kubler P. The management of gout. Australian Prescriber 2016;39:1 de agosto. [Ref.ID 100572]

20.

Anónimo. FDA approves Differin Gel 0.1% for over-the-counter use to treat acne. U.S. Food and Drug Administration 2016:8 de julio. [Ref.ID 100485]